Cytogem 200 mg Injection
Brand Name: Cytogem
Molecule: Gemcitabine
Strength: 200 mg
Quantity: 1 Vial
Form: Injection
Packaging Type: Vial
Manufacturer/Marketed By: Dr Reddys Laboratories Ltd
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
No similar products found.
Description
Cytogem 200 MG injection are manufactured by Dr. Reddy's Laboratories in India and contain 200 mg of Gemcitabine per injection. Each Vial includes Single vial, making Cytogem 200 MG injection an effective option for Chemotherapy . Prescription Required from your healthcare provider to purchase Gemcitabine medicine. Indogenmed deals in all type of generic Gemcitabine medicine.
Benefits
-
Acts as a chemotherapy agent targeting rapidly dividing cancer cells
-
May be used alone or in combination with other anticancer medicines
-
Used in multiple solid tumor cancers
-
Administered in controlled clinical settings under specialist supervision
-
Part of established chemotherapy protocols in oncology
Indications and Usage
Cytogem (gemcitabine) may be prescribed for the treatment of:
-
Pancreatic cancer
-
Non-small cell lung cancer (NSCLC)
-
Breast cancer
-
Ovarian cancer
-
Bladder cancer
-
Other cancers where gemcitabine-based chemotherapy is recommended by an oncologist
How it Works
Gemcitabine works by acting as a nucleoside analogue, meaning it resembles natural molecules used by cells to build DNA. During cancer cell division, gemcitabine becomes incorporated into the DNA chain and interferes with DNA synthesis. This disrupts the replication process and prevents cancer cells from multiplying. Additionally, gemcitabine inhibits enzymes required for DNA production, further limiting tumor cell growth. Through these mechanisms, the medicine may help control cancer progression when used as prescribed and monitored by an oncology specialist.
Dosage & Administration
-
Cytogem is administered as an intravenous infusion by healthcare professionals.
-
Infusion usually takes about 30 minutes, depending on the treatment regimen.
-
The dosage is determined based on body surface area, cancer type, and treatment protocol.
-
Chemotherapy cycles may include weekly infusions followed by rest periods as determined by the oncologist.
-
Dose adjustments may be required based on treatment response and side effects.
Side Effects
Common side effects
-
Nausea and vomiting
-
Loss of appetite
-
Hair loss
-
Fatigue
-
Fever or flu-like symptoms
-
Rash or itching
-
Low white blood cells or platelets
Serious side effects
-
Severe bone marrow suppression (low blood cell counts)
-
Liver function abnormalities
-
Severe infections
-
Lung problems or breathing difficulty
-
Kidney complications or fluid retention
Patients should inform their healthcare provider if they experience severe or persistent symptoms.
Warning and Precaution
-
May cause low blood cell counts, increasing infection risk
-
Regular blood tests are required during treatment
-
Risk of liver or kidney function changes
-
Avoid use during pregnancy unless specifically advised by a doctor
-
Not recommended during breastfeeding
-
Inform healthcare providers about all medicines and supplements being used
-
Live vaccines should generally be avoided during chemotherapy treatment
Patient Guidance
-
Treatment should be administered only by trained healthcare professionals
-
Attend all scheduled chemotherapy sessions and follow-up appointments
-
Regular blood tests may be required to monitor blood counts and organ function
-
Inform your doctor if you develop fever, infection symptoms, or unusual bleeding
-
Maintain good hydration and follow nutrition guidance provided by your care team
-
Do not stop or alter treatment without consulting your oncologist
Clinical Trial & Approvals
Gemcitabine has been evaluated in numerous clinical studies for several cancers including pancreatic, lung, ovarian, and breast cancers. These studies demonstrated its effectiveness as both single-agent therapy and in combination chemotherapy regimens, leading to regulatory approvals in many countries for various oncology indications.
References
-
Drugs.com – Gemcitabine Drug Information
https://www.drugs.com/mtm/gemcitabine.html -
Practo – Cytogem 200 mg Injection Overview
https://www.practo.com/medicine-info/cytogem-200-mg-injection-19877 -
Tata 1mg – Cytogem 200 mg Injection Uses & Side Effects
https://www.1mg.com/drugs/cytogem-200mg-injection-244458 -
TrueMeds – Cytogem 200 Injection Drug Information
https://www.truemeds.in/medicine/cytogem-200-mg-injection-1 -
Medindia – Gemcitabine Drug Information
https://www.medindia.net/drug-price/gemcitabine/cytogem-200-mg.htm
Prescription & documentation note
Cytogem 200 mg Injection is typically supplied against a valid prescription and administered in a hospital or oncology clinic. For international supply requests, patients may need to provide documentation such as a licensed physician’s prescription, medical records, and identification, depending on destination country regulations.
FAQ
What is Cytogem 200 mg Injection used for?
It is used in chemotherapy treatment for cancers such as pancreatic, lung, breast, ovarian, and bladder cancer.
What is the active ingredient in Cytogem?
The active ingredient is gemcitabine, a nucleoside analogue chemotherapy drug.
How is Cytogem administered?
It is given as an intravenous infusion in a hospital or oncology clinic.
Can Cytogem be used with other cancer medicines?
Yes. It is often used in combination with other chemotherapy drugs depending on the treatment plan.
How often is Cytogem given?
The dosing schedule depends on the cancer type and treatment protocol, typically given in cycles with rest periods.
Does Cytogem affect blood cells?
Yes. It may reduce blood cell counts, which is why regular blood tests are required during treatment.
Can Cytogem be used during pregnancy?
It is generally not recommended during pregnancy due to potential harm to the fetus.
Is Cytogem a prescription medicine?
Yes. Cytogem is a prescription-only chemotherapy medicine administered under medical supervision.
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve
READ MORE »May 6, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.